A Technical Feasibility Study of Dornase Alfa Delivery with eFlow® Vibrating Membrane Nebulizers: Aerosol Characteristics and Physicochemical Stability-Reference-Cited by-同舟云学术

A Technical Feasibility Study of Dornase Alfa Delivery with eFlow® Vibrating Membrane Nebulizers: Aerosol Characteristics and Physicochemical Stability

Published:2011-01 Issue:1 Volume:100 Page:98-109
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Scherer Thomas,Geller David E.,Owyang Laura,Tservistas Marcus,Keller Manfred,Boden Norbert,Kesser Kenneth C.,Shire Steven J.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference30 articles.

1. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum;Shak;Proc Natl Acad Sci USA,1990

2. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group [see comment];Fuchs;N Engl J Med,1994

3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities [see comment];Quan;J Pediatr,2001

4. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers;Cipolla;Pharm Res,1994

5. Assessment of aerosol delivery systems for recombinant human deoxyribonuclease;Cipolla;SPT Pharma Sci,1994

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Clonal and High-Yield Mammalian Cell Line for the Manufacturing of a Hyperactive Human DNase I with Extended Plasma Half-Life Using PASylation® Technology;Pharmaceutics;2024-07-22

2. New Generation Nebulizers;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2024-06-01

3. Effect of atomization on the composition and structure of recombinant humanized collagen type III;Journal of Applied Biomaterials & Functional Materials;2024-01

4. Recombinant Human Deoxyribonuclease I;Pharmaceutical Biotechnology;2024

5. Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study;European Journal of Pharmaceutical Sciences;2023-10